

1P-171-T025

Monoclonal Antibody to CD49d / Integrin alpha 4 Phycoerythrin (PE) conjugated (25 tests)

Clone: 9F10

Isotype: Mouse IgG1

Specificity: The mouse monoclonal antibody 9F10 recognizes CD49d (alpha 4 integrin), a

145-180 kDa type I transmembrane glycoprotein expressed on B and T cells, monocytes, eosinophils, basophils, NK cells, and dendritic cells, but not platelets.

HLDA V; WS Code S215

Regulatory Status: RUO

Species Reactivity: Human, Non-Human Primates, Bovine, Canine (Dog), Equine (Horse), Feline

(Cat), Sheep

Preparation: The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum

conditions. The conjugate is purified by size-exclusion chromatography and

adjusted for direct use. No reconstitution is necessary.

Storage Buffer: The reagent is provided in stabilizing phosphate buffered saline (PBS) solution

containing 15mM sodium azide.

Storage / Stability: Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not

use after expiration date stamped on vial label.

Usage: The reagent is designed for Flow Cytometry analysis of human blood cells using

10 μl reagent / 100 μl of whole blood or 10⁶ cells in a suspension.

The content of a vial (0.25 ml) is sufficient for 25 tests.

Expiration: See vial label

Lot Number: See vial label

Background: CD49d / integrin alpha 4, unlike other alpha integrins, neither contains an I-domain,

nor undergoes disulfide-linked cleavage. It associates with beta 7 chain to form alpha 4 / beta 7 integrin, and with beta 1 chain (CD29) to form VLA-4 integrin. These complexes are important for lymphocyte migration from circulation into tissue (binding VCAM-1) and homing of T cell subsets to Peyer's patches (binding MadCAM-1), but VLA-4 is also target for invasive bacteria which contain invasin. CD49d is essential for differentiation and migration of hematopoietic stem cells by their adhesion to bone marrow stromal cells, and provides a costimulatory signal to TCR-CD3 complex by inducing phosphorylation of some focal adhesion proteins.



PRODUCT DATA SHEET

References:

*Stenner MP, Waschbisch A, Buck D, Doerck S, Einsele H, Toyka KV, Wiendl H: Effects of natalizumab treatment on Foxp3+ T regulatory cells. PLoS One. 2008 Oct 6;3(10):e3319.

*Chigaev A, Waller A, Amit O, Halip L, Bologa CG, Sklar LA: Real-time analysis of conformation-sensitive antibody binding provides new insights into integrin conformational regulation. J Biol Chem. 2009 May 22;284(21):14337-46

*Schneider-Hohendorf T, Rossaint J, Mohan H, Böning D, Breuer J, Kuhlmann T, Gross CC, Flanagan K, Sorokin L, Vestweber D, Zarbock A, Schwab N, Wiendl H: VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. J Exp Med. 2014 Aug 25;211(9):1833-46.

*Yoon SO, Lee IY, Zhang X, Zapata MC, Choi YS: CD9 may contribute to the survival of human germinal center B cells by facilitating the interaction with follicular dendritic cells. FEBS Open Bio. 2014 Apr 13;4:370-6.

*Zhang XF, Feng MF: Adherence of human monocytes and NK cells to human TNF-alpha-stimulated porcine endothelial cells. Immunol Cell Biol. 2000 Dec;78(6):633-40.

*Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER: The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009 Sep;330(3):864-75.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.